Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo Gets Grant, Will Collaborate in Cancer PGx Study

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today said that it has received a grant from the Bavarian Research Foundation to expand applications of its quantitative phosphoproteomics platform to drug efficacy studies.

The amount of the grant was not disclosed. But as part of the award, Kinaxo will work with Priaxon, Genomatix Software, the Technical University Munich, and the University Hospital "Rechts der Isar" to perform a large-scale drug efficacy study. The goal of the collaboration is to identify tumor-relevant signal transduction pathways and develop new methods for individualized pancreatic cancer therapy.

Martinsreid, Germany-based Kinaxo said that quantification of phosphorylation patterns in relation to drug administration could deliver insights into a compounds cellular mode of action. It also could potentially "unveil the mechanisms of both cellular resistance and a drug's effect," the firm said.